跳至主要内容
临床试验/NCT02376595
NCT02376595已完成不适用

Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.

Pontificia Universidad Catolica de Chile0 个研究点目标入组 10 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
10
主要终点
strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle.

研究概览

简要总结

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Scheduled for elective surgery under general anesthesia.

排除标准

  • Pregnancy.
  • Body mass index (BMI) >25 kg/m
  • Anticipated difficult airway.
  • Surgery associated with great volume loss.
  • Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease.
  • Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade

研究组 & 干预措施

Rocuronium Bromide

Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.

干预措施: Rocuronium Bromide (Drug)

结局指标

主要结局

strength measuring 2 acceleromyograph. One Placed at the masseter muscle and the other one at the adductor pollicis muscle.

时间窗: 60 minutes

Measure blood concentrations after administration rocuronium

时间窗: 120 minutes

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验